{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:56:36Z","timestamp":1768553796417,"version":"3.49.0"},"posted":{"date-parts":[[2021,3,28]]},"group-title":"Epidemiology","reference-count":33,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Health officials warn that SARS-CoV-2 vaccines must be uniformly distributed within and among countries if we are to quell the ongoing pandemic. Yet there has been little critical assessment of the underlying reasons for this warning. Here, we explicitly show why vaccine equity is necessary. Perhaps counter-intuitively, we find that vaccine escape mutants are less likely to come from highly vaccinated regions where there is strong selection pressure favoring vaccine escape and more likely to come from neighboring unvaccinated regions where there is no selection favoring escape. Unvaccinated geographic regions thus provide evolutionary reservoirs from which new strains can arise and cause new epidemics within neighboring vaccinated regions and beyond. Our findings have timely implications for vaccine rollout strategies and public health policy.<\/jats:p>","DOI":"10.1101\/2021.03.27.21254453","type":"posted-content","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T05:25:15Z","timestamp":1616909115000},"source":"Crossref","is-referenced-by-count":4,"title":["How unequal vaccine distribution promotes the evolution of vaccine escape"],"prefix":"10.64898","author":[{"given":"Philip J","family":"Gerrish","sequence":"first","affiliation":[]},{"given":"Fernando","family":"Salda\u00f1a","sequence":"additional","affiliation":[]},{"given":"Benjamin","family":"Galeota-Sprung","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Colato","sequence":"additional","affiliation":[]},{"given":"Erika E","family":"Rodriguez","sequence":"additional","affiliation":[]},{"given":"Jorge X Velasco","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2021040308150750000_2021.03.27.21254453v3.1","unstructured":"Roser, M. , Ritchie, H. , Ortiz-Ospina, E. & Hasell, J. Coronavirus Pandemic (COVID-19). Our World in Data (2021)."},{"key":"2021040308150750000_2021.03.27.21254453v3.2","doi-asserted-by":"crossref","unstructured":"Hoffmann, M. , Arora, P. , Gro\u00df, R. , et al. SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination. bioRxiv, 2021.02.11.430787 (Feb. 2021).","DOI":"10.1101\/2021.02.11.430787"},{"key":"2021040308150750000_2021.03.27.21254453v3.3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.2021.1114","article-title":"SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"2021040308150750000_2021.03.27.21254453v3.4","doi-asserted-by":"crossref","unstructured":"Garcia-Beltran, W. F. , Lam, E. C. , St. Denis, K. , et al. Multiple SARS-CoV-2 variants escape neutral-ization by vaccine-induced humoral immunity. Cell (Mar. 2021).","DOI":"10.1016\/j.cell.2021.03.013"},{"key":"2021040308150750000_2021.03.27.21254453v3.5","unstructured":"Wang, P. , Nair, M. S. , Liu, L. , et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature (Mar. 2021)."},{"key":"2021040308150750000_2021.03.27.21254453v3.6","unstructured":"Collier, D. A. , De Marco, A. , Ferreira, I. A. T. M. , et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. medRxiv (Feb. 2021)."},{"key":"2021040308150750000_2021.03.27.21254453v3.7","doi-asserted-by":"crossref","unstructured":"Wise, J. Covid-19: The E484K mutation and the risks it poses. BMJ 372, 359 (Feb. 2021).","DOI":"10.1136\/bmj.n359"},{"key":"2021040308150750000_2021.03.27.21254453v3.8","doi-asserted-by":"crossref","unstructured":"Van Egeren, D. , Novokhodko, A. , Stoddard, M. , et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. bioRxiv (Nov. 2020).","DOI":"10.1101\/2020.11.17.20233726"},{"key":"2021040308150750000_2021.03.27.21254453v3.9","doi-asserted-by":"crossref","unstructured":"Greaney, A. J. , Loes, A. N. , Crawford, K. H. D. , et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. bioRxiv, 2020.12.31.425021 (Jan. 2021).","DOI":"10.1101\/2020.12.31.425021"},{"key":"2021040308150750000_2021.03.27.21254453v3.10","unstructured":"Faria, N. R. , Mellan, T. A. , Whittaker, C. , et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv (Mar. 2021)."},{"key":"2021040308150750000_2021.03.27.21254453v3.11","doi-asserted-by":"crossref","unstructured":"Abdool Karim, S. S. & de Oliveira, T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N. Engl. J. Med. (Mar. 2021).","DOI":"10.1056\/NEJMc2100362"},{"key":"2021040308150750000_2021.03.27.21254453v3.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg4493"},{"key":"2021040308150750000_2021.03.27.21254453v3.13","doi-asserted-by":"crossref","unstructured":"Eguia, R. , Crawford, K. H. D. , Stevens-Ayers, T. , et al. A human coronavirus evolves antigenically to escape antibody immunity. bioRxiv.org (Mar. 2021).","DOI":"10.1101\/2020.12.17.423313"},{"key":"2021040308150750000_2021.03.27.21254453v3.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.02.018"},{"key":"2021040308150750000_2021.03.27.21254453v3.15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075030"},{"key":"2021040308150750000_2021.03.27.21254453v3.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.20.11514"},{"key":"2021040308150750000_2021.03.27.21254453v3.17","doi-asserted-by":"publisher","DOI":"10.1078\/1438-4221-00196"},{"key":"2021040308150750000_2021.03.27.21254453v3.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1318"},{"key":"2021040308150750000_2021.03.27.21254453v3.19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2148-13-22"},{"key":"2021040308150750000_2021.03.27.21254453v3.20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004142"},{"key":"2021040308150750000_2021.03.27.21254453v3.21","doi-asserted-by":"crossref","unstructured":"Blanquart, F. , Lehtinen, S. , Lipsitch, M. & Fraser, C. The evolution of antibiotic resistance in a structured host population. J. R. Soc. Interface 15 (June 2018).","DOI":"10.1098\/rsif.2018.0040"},{"key":"2021040308150750000_2021.03.27.21254453v3.22","doi-asserted-by":"crossref","first-page":"e1008010","DOI":"10.1371\/journal.pcbi.1008010","article-title":"Population structure across scales facilitates co-existence and spatial heterogeneity of antibiotic-resistant infections","volume":"16","year":"2020","journal-title":"PLoS Comput. Biol"},{"key":"2021040308150750000_2021.03.27.21254453v3.23","doi-asserted-by":"crossref","unstructured":"Gog, J. R. , Hill, E. M. , Danon, L. & Thompson, R. Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model. medRxiv (Mar. 2021).","DOI":"10.1101\/2021.03.14.21253544"},{"key":"2021040308150750000_2021.03.27.21254453v3.24","doi-asserted-by":"publisher","DOI":"10.1186\/s13584-021-00440-6"},{"key":"2021040308150750000_2021.03.27.21254453v3.25","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3012"},{"key":"2021040308150750000_2021.03.27.21254453v3.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30196-1"},{"key":"2021040308150750000_2021.03.27.21254453v3.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbs.2020.108370"},{"key":"2021040308150750000_2021.03.27.21254453v3.28","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3934\/mbe.2020330","article-title":"Lifting mobility restrictions and the effect of superspreading events on the short-term dynamics of COVID-19","volume":"17","year":"2020","journal-title":"Math. Biosci. Eng"},{"key":"2021040308150750000_2021.03.27.21254453v3.29","doi-asserted-by":"crossref","unstructured":"Salda\u00f1a, F. & Velasco-Hern\u00e1ndez, J. X. The trade-off between mobility and vaccination for COVID-19 control: a metapopulation modeling approach. bioRxiv (Mar. 2021).","DOI":"10.1101\/2020.12.09.20246538"},{"key":"2021040308150750000_2021.03.27.21254453v3.30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.vaccine.2020.11.039","article-title":"Coping with COVID","volume":"39","year":"2021","journal-title":"Vaccine"},{"key":"2021040308150750000_2021.03.27.21254453v3.31","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00396-2"},{"key":"2021040308150750000_2021.03.27.21254453v3.32","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, A. Toward the next-generation COVID-19 vaccines that circumvent antigenic drift while defusing viral infection. ACS Pharmacol. Transl. Sci. (Mar. 2021).","DOI":"10.1021\/acsptsci.1c00054"},{"key":"2021040308150750000_2021.03.27.21254453v3.33","doi-asserted-by":"crossref","unstructured":"Moore, J. P. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. JAMA, E1\u20132 (Mar. 2021).","DOI":"10.1001\/jama.2021.3465"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2021.03.27.21254453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:11:56Z","timestamp":1768486316000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.03.27.21254453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,28]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1101\/2021.03.27.21254453","relation":{},"subject":[],"published":{"date-parts":[[2021,3,28]]},"subtype":"preprint"}}